Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 03/25/2021

Summary

Jacqueline E. Shea, Chief Operating Officer of INOVIO PHARMACEUTICALS, INC. [ INO ], reports 16,667 Restricted Stock Units settled in Common Stock on 03/25/2021, with 7,247 shares withheld by the issuer at $ 9.06 to satisfy tax withholding. On 03/26/2021, 4,710 shares were sold at $ 8.97 under a Rule 10b5-1 trading plan. The 50,000-unit award vested 16,667 shares on March 25, 2020 and on March 25, 2021, with 16,666 due on March 25, 2022. Direct holdings after the sale are 60,127 shares; the form is signed /s/ Jacqueline E. Shea, 03/26/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Shea Jacqueline Elizabeth (Last) (First) (Middle) 660 W. GERMANTOWN PIKE (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | Shea Jacqueline Elizabeth | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Operating Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Operating Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 03/25/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 03/25/2021 | M | 16,667 | A | (1) | 72,084 | D
Common Stock | 03/25/2021 | F (2) | 7,247 | D | $ 9.06 | 64,837 | D
Common Stock | 03/26/2021 | S (3) | 4,710 | D | $ 8.97 | 60,127 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Restricted Stock Unit | (1) | 03/25/2021 | M | 16,667 | (1) | (1) | Common Stock | 16,667 | $ 0 (1) | 16,666 | D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
2. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Remarks:
/s/ Jacqueline E. Shea | 03/26/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_INO_4_filed2021-03-26_0001055726-21-000034.xml

Size

18,144 bytes

SHA-256

5206d0c9e9d3a60a3c12f03c850196752f696cd12849bc7ff29a9749dcffe3c6

Our copy

SEC_INO_4_filed2021-03-26_0001055726-21-000034.xml

Original

www.sec.gov